集体诉讼指控 Altimmune Inc. 夸大了 pemvidutide 的潜力，存在证券欺诈行为。 Class-action lawsuits allege securities fraud against Altimmune Inc. for overstating pemvidutide's potential.
针对 Altimmune Inc. 提起的集体诉讼指控其存在证券欺诈，声称该公司夸大了其主要候选产品 pemvidutide 的潜力及其临床、商业和竞争前景。 Class-action lawsuits filed against Altimmune Inc. allege securities fraud, claiming the company overstated the potential of its lead product candidate, pemvidutide, and its clinical, commercial, and competitive prospects. 在 2023 年 12 月 1 日至 2024 年 4 月 26 日期间购买 Altimmune 股票的投资者可能有资格获得恢复。 Investors who purchased Altimmune shares between December 1, 2023, and April 26, 2024, may be eligible for recovery. 代表投资者的律师事务所包括 Levi & Korsinsky、Bronstein、Gewirtz & Grossman 和 Bernstein Liebhard LLP。 Law firms representing investors include Levi & Korsinsky, Bronstein, Gewirtz & Grossman, and Bernstein Liebhard LLP.